Metoprolol metabolism via cytochrome P4502D6 in ethnic populations

Drug Metabolism and Disposition

Volumn 24, Issue 3, 1996, Pages 350-355

  Johnson, Julie A ^a   Burlew, Brad S ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; METOPROLOL TARTRATE; QUINIDINE SULFATE;

ADULT; ARTICLE; CHIRALITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; ENZYME ACTIVITY; ETHNIC GROUP; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RACE DIFFERENCE; STEREOCHEMISTRY;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; ANTIHYPERTENSIVE AGENTS; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP2D6; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; MALE; METOPROLOL; MOLECULAR CONFORMATION; QUINIDINE;

PIERINAE;

EID: 0029919063     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. A. J. J. Wood and H. H. Zhou: Ethnic differences in drug disposition and responsiveness. Clin. Pharmacokinet. 20, 350-373 (1991).
2. H. H. Zhou, R. P. Koshakji, D. J. Silberstein, G. R. Wilkinson, and A. J. J. Wood: Racial differences in drug response: altered sensitivity to and clearance of propranolol in men of Chinese descent and compared with American whites. N. Engl. J. Med. 320, 565-570 (1989).
3. M. M. Ghonein, K. Korttila, C. K. Chiang, et al.: Diazepam effects and kinetics in Caucasians and Orientals. Clin. Pharmacol. Ther. 29, 749-756 (1981).
4. B. J. Materson, J. R. Domenic, W. C. Cushman, et al. for the Veterans Affairs Cooperative Study Group on Antihypertensive Agents: Single drug therapy for hypertensive men. A comparison of six antihypertensive agents with placebo. N. Engl. J. Med. 328, 914-921 (1993)
5. K. M. Lin, J. K. Lau, R. Smith, P. Phillips, E. Antal, and R. E. Poland: Comparison of alprazolam plasma levels in normal Asian and Caucasian male volunteers. Psychopharmacalogy 96, 365-369 (1988).
6. T. Shimada, H. Yamazaki, M. Mimura, Y. Inui, and F. P. Guengerich: Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270, 414-423 (1994).
7. M. V. Relling, J. S. Lin, G. D. Ayers, and W. E. Evans: Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities. Clin. Pharmacol. Ther. 52, 643-658 (1992).
8. H. L. McLeod, L. Fang, X. Luo, E. P. Scott, and W. E. Evans: Ethnic differences in erythrocyte catechol-O-methyltransferase activity in black and white Americans. J. Pharmacol. Exp. Ther. 270, 26-29 (1994).
9. H. L. McLeod, J. S. Lin, E. P. Scott, C. H. Pui, and W. E. Evans. Thiopurine merhyltransferase activity in Amencan white subjects and black subjects. Clin. Pharmacol Ther. 55, 15-20 (1994).
10. J. A. Johnson and B. S. Burlew: Racial differences in propranolol pharmacokinetics. Clin. Pharmacol. Ther. 51, 495-500 (1992).
11. K. M. Sowinski, J. J. Lima, B. S. Burlew, J. D. Massie, and J. A. Johnson: Racial differences in propanolol enantiomer kinetics following simultaneous iv and oral administration. Br. J. Clin. Pharmacol., in press.
12. S. A. Ward, T. Walle, U. K. Walle, G. R. Wilkinson, and R. A. Branch: Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities. Clin. Pharmacol. Ther. 45, 72-79 (1989).
13. H. H. Zhou, L. B. Abernathy, D. M. Roden, and A. J. J. Wood: Quinidine reduces clearance of (+)-propranolol more than (-)-propranolol through marked reduction in 4-hydroxylation. Clin. Pharmacol. Ther. 47, 686-693 (1990).
14. M V. Relling and W. E. Evans: Genetic polymorphisms of drag metabolism. In "Applied Pharmacokinetics" (W. E. Evans, J. J. Schentag, W. J. Jusko, eds.), 3rd ed., chap. 7. Applied Therapeutics, Vancouver, WA, 1992.
15. U. M. Zanger, F. Vilbois, J. P. Hardwick, and U. A. Meyer: Absence of hepatic cytochrome P450bufl causes genetically deficient debrisoquin oxidation in man. Biochemistry 27, 5447-5454 (1988).
16. M. V. Relling, J. Cherrie, M. J. Schell, W. P. Petros, and W. E. Evans: Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in American black versus white subjects. Clin. Pharmacol. Ther. 50, 308-313 (1991).
17. M. S. Lennard, J. H. Silar, A. J. Smith, and G. T. Tucker: Oxidative phenotype - a major determinant of metoprolol metabolism and response. N. Engl. J. Med. 307, 1558-1560 (1982).
18. M. S. Lennard, G. T. Tucker, J. H. Silar, S. Freestone, L. E. Ramsay, and H. F. Woods: Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquin metabolizers. Clin. Pharmacol. Ther. 34, 732-737 (1983).
19. 2-receptor pharmacodynamics of metoprolol and its enantiomers. J. Pharmacol. Exp. Ther 256, 959-966 (1991).
20. T. L. O'Rear, S. M. Borcherding, and R. L. Laionde: Dextromethorphan does not alter metoprolol enantiomer disposition. Clin. Pharmacol. Ther. 49, 159 (abstr.) (1991).
21. 3H-metoprolol in man, the dog and the rat. Acta Pharmacol. Toxicol. 36, (Suppl. 5), 125-135 (1975).
22. S. V. Otton, H. K. Crewe, M. S. Lennard, G. T. Tucker, and H. F. Woods: Use of quinidine inhibition to define the role of the sparteine/debnsoquine cytochrome P450 in metoprolol oxidation by human liver microsomes. J. Pharmacol Exp. Ther. 247, 242-247 (1988).
23. T. Leeman, P. Dayer, and U. A. Meyer: Single-dose quinidine treatment inhibits metoprolol oxidation in extensive metabolizers. Eur. J. Clin. Pharmacol. 29, 739-741 (1986).
24. C. Funck-Brentano, J. Turgeon, R. L. Woosley, and D. M. Roden: Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of genetic polymorphism. J. Pharmacol. Exp. Ther. 249, 134-142 (1989).
25. C. Funck-Brentano, H. K. Kroemer, H. Pavlou, R. L. Woosley, and D. M. Roden: Genetically-determined interaction between propafenone and low dose quinidine: role of active metabolites in modulating net drug effect. Br. J. Clin. Pharmacol. 27, 435-444 (1989).
26. M. D. Nielsen, K. Brosen, and L. F. Gram: A dose-effect study of the in vivo inhibitory effect of quinidine on sparteine oxidation in man. Br. J. Clin. Pharmacol. 29, 299-304 (1990).
27. W. E. Evans, M. V. Relling, W. P. Petros, W. H. Meyer, J. Mirro, and W. R. Crom: Dextromethorphan and caffeine as probes for simultaneous determination of debrisoquin oxidation and N-acetylation phenotypes in children. Clin Pharmacol Ther. 45, 568-573 (1989).
28. V. L. Herring, T. L. Bastian, and R. L. Laionde: Solid-phase extraction and direct high performance liquid Chromatographic determination of metoprolol enantiomers in plasma. J. Chromatogr. 567, 221-227 (1991).
29. P. H. Marathe, D. D Shen, and W. L. Nelson: Metabolic kinetics of pseudoracemic propranolol in human liver microsomes. Enantioselectivity and quinidine inhibition. Drug Metab. Dispos. 22, 237-247 (1994).